Clinical study of plasma thrombomodulin detection

Area of Science:

• Biochemistry
• Clinical Medicine
• Pathophysiology

Background:

• Plasma thrombomodulin (PTM) is a crucial protein in the regulation of coagulation and inflammation.
• Its clinical significance in various disease states requires further elucidation.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of plasma thrombomodulin (PTM) in diverse diseases and their complications.
• To establish PTM as a potential biomarker for disease severity and therapeutic response.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure PTM levels in 979 patients and 60 healthy controls.
• Statistical analyses were performed to compare PTM levels across different disease groups and severity levels.

Main Results:

• Elevated PTM levels were observed in patients with chronic renal failure, sepsis, multiple organ failure, systemic lupus erythematosus with albuminuria, and diabetic complications.
• PTM demonstrated good sensitivity and specificity in differentiating disease severity and complications, with varying positive criteria (e.g., >70 microg/L for CRF, >50 microg/L for sepsis).
• PTM levels correlated with clinical progression in acute leukemia, multiple myeloma, and cancer, and were higher in microangiopathy compared to macroangiopathy.

Conclusions:

• Plasma thrombomodulin (PTM) is a valuable indicator for assessing disease severity, predicting complications, and evaluating therapeutic effectiveness across a spectrum of clinical conditions.
• PTM serves as a reliable criterion for evaluating microangiopathy and its associated clinical manifestations.